HOME >> BIOLOGY >> NEWS
Stem-cell therapy could have benefits and risks for heart-attack PTs

Two studies in this week's issue of THE LANCET raise questions about the feasibility and safety of stem-cell therapy for heart disease, suggesting that such treatments could have both benefits and drawbacks.

Adult haemopoietic stem cells give rise to blood cells, and are thought to be able to generate other types of cell. Recent studies have investigated the potential of stem cells to reverse heart damage caused by diseases such as acute myocardial infarction (heart attack). Use of granulocyte-colony stimulating factor (G-CSF) to mobilise stem cells has shown promise, but its safety has not been tested in patients with myocardial infarction.

Hyun-Jae Kang, Huo-Soo Kim, and colleagues from Seoul National University, Republic of Korea, studied 27 patients with stable myocardial infarction who underwent coronary stenting. After follow-up assessment in 11 patients, the investigators noted improved heart function in the seven who were randomly assigned to receive an infusion of their own peripheral blood stem-cells and G-CSF. However, an unexpectedly high rate of in-stent restenosis (recurrence of coronary artery narrowing) was seen in patients given G-CSF, either alone or in combination with stem-cell infusion, and therefore trial enrolment was stopped.

In a Research letter (p 783), Richard Vulliet from the University of California and colleagues report that after being injected with bone-marrow stem-cells, evidence of myocardial infarction was seen in the hearts of dogs.

In a Commentary (p 746), Hiroaki Matsuba (Kyoto University Hospital, Japan) notes that these potential complications should be investigated thoroughly before such methods are more widely used in patients.

Contact:
Dr. Hyo-Soo Kim, Department of Internal Medicine, Seoul National University Hospital, 28 Yongon-dong, Chongno-gu, Seoul 110-744, Republic of Korea. T) 82-2-760-2226; F) 82-2-766-8904; E) hyosoo@snu.ac
'"/>


Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
3-Mar-2004


Page: 1 2

Related biology news :

1. Stem-cell research and reproductive cloning laws should be separate
2. Stem-cell defect underlies common genetic disorder
3. Targeted therapy knocks out pediatric brain cancer in mice
4. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers
5. Columbia research to examine gene influence on severity of peridontal disease, therapy response
6. Case for IBD combination therapy comes from research at Baylor, MIT and Hebrew University
7. The search for a kinder, gentler chemotherapy
8. Embryonic stem cell therapy shows steady benefits in rebuilding infarcted heart
9. Retroviral gene therapy? ASLV, HIV, and MLV show distinct target site preferences
10. Gene changes linked to increased eye pressure may have implications for glaucoma therapy
11. Jefferson Lab detector technology aids development of cystic fibrosis therapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/8/2019)... (PRWEB) , ... January 07, 2019 , ... ... and compliance solutions, is proud to welcome Thomas Kennedy as head of sales ... Miglicco, CEO for PureWay. , Mr. Kennedy has previously worked for Johnson & ...
(Date:1/7/2019)... ... January 07, 2019 , ... Franz Inc. , ... technology for Knowledge Graphs solutions, announced that it was recognized by Database ... DBTA’s data and information management recognition list includes newer approaches leveraging artificial intelligence, ...
(Date:1/4/2019)... (PRWEB) , ... January 03, 2019 , ... ... adopt 3D cell culture models into their drug discovery research workflows with biology ... improve the in vivo relevancy of in vitro studies, they create several challenges ...
Breaking Biology News(10 mins):
(Date:12/20/2018)... Colo. (PRWEB) , ... December 20, 2018 , ... New ... 2019, with major changes in regulations in the European Union (EU) on the horizon, ... companies to consider. , “The transition to the EU Medical Device Regulation (MDR), digital ...
(Date:12/19/2018)... ... December 19, 2018 , ... ... the validated release of Limfinity® version 7.1. The new release enhances the latest ... RURO as 2018 comes to an end. , Validation protocols, and their execution, ...
(Date:12/18/2018)... ... December 18, 2018 , ... USDM ... for the life sciences industry, unveiled a completely redesigned website at http://www.usdm.com ... user-friendly browsing experience for their valued clients and business partners. , The ...
(Date:12/14/2018)... ... December 14, 2018 , ... NOVA OCULUS PARTNERS, LLC, ... green light to immediately begin a clinical patient trial in Edmonton using their ... of Health Canada has granted what is called an Investigational Testing Authorization for ...
Breaking Biology Technology:
Cached News: